A recent clinical trial published in the European Heart Journal Open has associated the multi-ingredient longevity supplement NOVOS Core with notable improvements in arterial health and reductions in systolic blood pressure. Spearheaded by researchers at the University of Surrey and led by Christian Heiss, Professor of Cardiovascular Medicine, the randomized, double-blind, placebo-controlled study investigated whether a complex formulation designed to combat the biological hallmarks of aging could positively impact human vascular function over a six-month period. While the results indicate promising physiological benefits—including a significant enhancement in flow-mediated dilation and a decrease in pulse wave velocity—independent experts emphasize the necessity for replication due to study limitations, such as high participant attrition and age discrepancies between the test and control cohorts.

To better understand the implications of this study, it is helpful to examine the mechanics of vascular aging, the composition of the tested supplement, the design and execution of the clinical trial, expert evaluations from the broader medical community, and the potential future trajectory of multi-ingredient longevity interventions in mainstream cardiology.

The Mechanics of Vascular Aging and the Longevity Hypothesis

The human cardiovascular system undergoes progressive structural and functional deterioration as individuals age. At the center of this decline is the endothelium, the delicate inner lining of blood vessels. Healthy endothelial cells continuously sense changes in blood flow and release signaling molecules, such as nitric oxide, which command the surrounding smooth muscle tissue to relax, thereby accommodating increased blood volume. With advancing age, however, the endothelium typically becomes less responsive to these vital hemodynamic signals.

Simultaneously, large arteries tend to lose their youthful elasticity, growing stiffer and less compliant. This arterial stiffening forces the heart to work harder to pump blood through the circulatory network, frequently culminating in elevated systolic blood pressure. Several interconnected molecular and cellular processes drive this vascular degradation, including chronic low-grade inflammation, heightened oxidative stress, mitochondrial dysfunction, and the accumulation of senescent cells.

While conventional pharmacological interventions generally target isolated risk factors—such as prescribing statins for hyperlipidemia or specific antihypertensive drugs for high blood pressure—the contemporary longevity research sector increasingly focuses on multi-target formulations. NOVOS Core was engineered specifically to address these overlapping pathways of aging simultaneously. Rather than isolating a single botanical extract or amino acid, the supplement combines a diverse cocktail of compounds purported to support cellular health, metabolic function, and antioxidant defenses.

Ingredients and Formulation of NOVOS Core

The proprietary blend investigated in the University of Surrey trial comprises twelve distinct active ingredients. The formulation features glycine, calcium alpha-ketoglutarate, glucosamine sulfate, magnesium malate, vitamin C, L-theanine, fisetin, pterostilbene, hyaluronic acid, lithium aspartate, and concentrated extracts of rhodiola and ginger.

According to the manufacturer, each component was selected based on pre-existing, peer-reviewed scientific literature pointing toward specific anti-aging or metabolic mechanisms. For instance, alpha-ketoglutarate has been studied for its role in cellular metabolism and epigenetic regulation, while fisetin and pterostilbene are well-known flavonoids investigated for their antioxidant and senolytic properties. Glycine and magnesium play crucial roles in metabolic and neurological homeostasis, and various botanical extracts contribute to cellular stress resistance.

Despite the individual theoretical backing of these ingredients, the clinical trial did not attempt to isolate the distinct contributions or mechanisms of action of each compound. Instead, researchers evaluated the entire multi-ingredient powder formulation as a single holistic intervention. Consequently, while observed physiological changes can be attributed to the daily consumption of the supplement as a whole, it remains scientifically unknown which specific ingredient—or synergistic combination of ingredients—drove the reported cardiovascular improvements.

Chronology and Design of the Clinical Trial

The investigation followed a rigorous randomized, double-blind, placebo-controlled protocol to minimize bias and control for placebo effects. The supplement and matching placebo powders were supplied by NOVOS, which also provided financial support for the study.

The trial enrolled 61 generally healthy, non-smoking adult participants with normal to mildly elevated blood pressures. Individuals with unstable cardiovascular diseases or severe clinical hypertension were intentionally excluded from the study population. Participants were instructed to consume one 15-gram dose of the powder daily.

The study design evaluated both acute and sustained chronic effects across three distinct temporal checkpoints:

  1. Baseline: Vascular function was assessed immediately before the administration of the very first dose.
  2. Acute Response: Measurements were taken one hour post-dose to capture immediate physiological reactions.
  3. Long-Term Follow-Up: Final vascular assessments were conducted at six months, timed precisely 24 hours after the most recent dose to minimize acute residual effects, though the study authors acknowledged that a complete elimination of short-term impacts could not be entirely guaranteed.

Out of the 61 initially enrolled participants, only 43 successfully completed the trial and were included in the primary analysis, resulting in 24 subjects in the supplement arm and 19 in the placebo arm. A notable portion of the attrition remained unexplained. Furthermore, a demographic discrepancy emerged between the two groups: the control group was notably older on average, registering around 59 to 60 years of age compared to 53 to 54 years in the supplement cohort. Given that the study specifically aimed to investigate age-related vascular changes, this baseline age gap represents a notable methodological limitation.

Longevity Supplement Improved Blood Vessels in a Human Trial

Key Findings: Vascular Function, Arterial Stiffness, and Blood Pressure

Despite the challenges posed by participant dropout and baseline age variances, the primary and secondary endpoints revealed statistically significant physiological shifts in the active treatment group compared to the placebo group.

The primary endpoint of the study was flow-mediated dilation (FMD), a standard non-invasive metric of endothelial health evaluated by measuring how significantly an arm artery widens when blood flow is abruptly restored after the release of a pressure cuff. At the six-month mark, FMD increased by an average of 2.6 percentage points in the supplement group—surging from approximately 5.5% to 8.1%—while remaining relatively flat in the placebo group. When adjusted for baseline characteristics, the net improvement versus placebo stood at 2.9 percentage points. Interestingly, the acute measurement taken just one hour after the very first dose showed an even larger immediate increase of 3.4 percentage points, highlighting an immediate vascular responsiveness to the mixture.

Secondary metrics further supported these cardiovascular improvements. Pulse wave velocity (PWV), an indicator of arterial stiffness measuring the speed at which pressure waves travel through the arterial tree, decreased by 0.78 meters per second in the supplement group at six months, while increasing by 0.56 meters per second among the controls. The adjusted between-group difference for PWV reached -1.18 meters per second, pointing toward a clearer, sustained structural benefit over the six-month duration rather than a fleeting acute reaction.

Systolic blood pressure also demonstrated a marked reduction. Over the six-month trial, average systolic blood pressure dropped by 8.5 mmHg in the supplement arm, compared to a modest 1.5 mmHg decline in the placebo cohort, yielding an adjusted between-group difference of 6.1 mmHg. Conversely, diastolic blood pressure readings showed no statistically significant differences between the two groups.

Importantly, blood lipid profiles—including total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides—showed no significant variations between groups. This absence of lipid modification strongly suggests that the observed vascular enhancements were driven by direct endothelial and structural mechanisms rather than systemic alterations in circulating blood fats. Consequently, calculated ten-year cardiovascular risk scores improved modestly for the supplement group, driven primarily by the downward shift in systolic blood pressure.

Expert Reactions and Critical Analysis

The publication of these findings has stimulated considerable discussion within the broader longevity medicine and cardiology communities.

Lead researcher Professor Christian Heiss expressed enthusiasm for the outcomes in an official press release, noting that the hypothesis regarding whether a multi-component supplement could successfully target multiple biological pathways of vascular aging was validated by the favorable six-month data concerning endothelial function, arterial stiffness, and systolic blood pressure.

However, independent medical professionals have urged caution, pointing out both the remarkable magnitude of the results and the inherent limitations of the study. Dr. Brad Stanfield, a longevity physician and medical commentator not involved in the research, remarked to industry journalists that the effect size was surprisingly large. He noted that a nearly 3-percentage-point rise in FMD is more than double the improvements typically achieved by powerful dietary interventions like cocoa flavanols in prior trials conducted by similar research groups.

Dr. Stanfield also contextualized the clinical relevance of surrogate markers, observing that while individuals with higher FMD scores statistically experience fewer cardiovascular events, no existing clinical trial has definitively proven that artificially elevating FMD via a specific treatment directly prevents heart attacks or strokes. Nevertheless, he acknowledged that a sustained 6-mmHg drop in systolic blood pressure would carry profound clinical significance if replicable in larger, more diverse populations.

Addressing the methodological vulnerabilities of the study, Dr. Stanfield highlighted the nearly one-third attrition rate and the persistent age imbalance between the control and intervention groups. He concluded that independent research teams must successfully replicate these findings before definitive medical recommendations or widespread conclusions can be established.

Broader Implications for Preventive Cardiology and Longevity Science

The intersection of multi-ingredient nutraceutical formulation and rigorous clinical validation represents a significant evolution in the longevity sector. Historically, many commercial anti-aging supplements have relied entirely on theoretical biochemistry, in vitro cell studies, or animal models without subjecting their final consumer products to human randomized controlled trials.

By funding and participating in a peer-reviewed, double-blind trial published in a respected cardiology journal, manufacturers of multi-component supplements are setting a higher evidentiary standard for the industry. If subsequent, larger-scale trials confirm that complex nutritional blends can safely and effectively lower systolic blood pressure and improve arterial elasticity, it could pave the way for a new class of preventive cardiology interventions. These adjunctive strategies could potentially complement traditional pharmacotherapy in mitigating the global burden of age-related cardiovascular disease.

For now, the medical consensus remains measured. While the six-month data linking NOVOS Core to improved artery function and reduced blood pressure offers an encouraging glimpse into the future of vascular health optimization, patients and clinicians await broader, longer-term trials featuring larger sample sizes, minimized attrition, and rigorous replication by independent academic institutions.

By Nana Wu